NMUR2

NMUR2

A gene on chromosome 5q33.1 that encodes a neuromedin U (NMU) receptor of the Gq/11-protein-coupled receptor family, which is expressed in the CNS—especially in the substantia nigra, medulla oblongata and pontine reticular formation. NMU receptors mediate various biological effects, including uterine contraction, vasoconstriction and activation of the hypothalamic-pituitary-adrenal (HPA) axis, resulting in decreased food intake via the corticotropin releasing hormone (CRH) system.
References in periodicals archive ?
We found that 5 genes (NMUR2, GHSR, NMBR, GNRHR, and F2RL3) in the attractor module were enriched in the pathway of neuroactive ligand-receptor interaction.
In the functional pathway of neuroactive ligand-receptor interaction, 5 genes NMUR2, GHSR, NMBR, GNRHR, and F2RL3 were involved.
Row Genes Evidence 1 NMUR2 [26] [29] 2 GHSR [27] [30] 3 NMBR [28] [31] 4 GNRHR [29] [32] 5 F2RL3 [30] [33] TABLE 3: Module-related genes and the drugs targeted for these genes detected from GeneCards database.
No mRNA expression information of three of genes, muscarinic acetylcholine receptor M1 (CHRM1), G-protein coupled receptor TGR-1 (NMUR2), and taste receptor type 2 member 31 (TAS2R31), was found in the BioGPS.
Interestingly, the effect of [proNMU.sub.104-136] does not appear to be mediated by NmU receptor 2 (NMUR2), the NmU receptor expressed preferentially in the brain (see later discussion of energy homeostasis and feeding).
Point-mutation studies have revealed that changes in amino acid sequence may alter binding of NmU to its receptors, NMUR1 and NMUR2; for example, substitution of certain residues may not affect NmU activity at NMUR2, but reduces the response mediated by NMUR1 (13).
Moreover, NmS binds to NmU receptors NMUR1 and NMUR2, with some data suggesting that NMUR2 has higher affinity for NmS than for NmU (16).
Two different receptors exist for NmU, termed NMUR1 (also known as GPR66 and FM-3) and NMUR2 (also known as TGR-1 and FM-4), encoded by genes located in human chromosomes 2 and 5, respectively (14, 28, 29, 35-39).
M2 EQUITYBITES-February 22, 2012-Omeros Corporation wins USD1m NIDA grant for non addicting NMUR2 drug development programme(C)2012 M2 COMMUNICATIONS http://www.m2.com
Biopharmaceutical company Omeros Corporation (NASDAQ:OMER) reported on Tuesday the receipt of a grant, valued at USD1.04m, from the National Institute on Drug Abuse (NIDA) to fund further drug development against neuromedin U receptor 2 (NMUR2).
This NIDA grant will be used to fund medicinal chemistry for proprietary compounds that interact with NMUR2 and the company will retain ownership of any compounds developed from the grant.
According to the company, NMUR2 is a non-orphan G protein-coupled receptor (GPCR) linked to pain.